These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30058866)

  • 1. A systematic review of the safety of incretin-based therapies in type 2 diabetes.
    Evans M; Bain SC; Vora J
    Expert Rev Endocrinol Metab; 2016 Mar; 11(2):217-232. PubMed ID: 30058866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Gao L; Yu S; Cipriani A; Wu S; Huang Y; Zhang Z; Yang J; Sun Y; Yang Z; Chai S; Zhang Y; Ji L; Zhan S; Sun F
    Aging Dis; 2019 Dec; 10(6):1311-1319. PubMed ID: 31788342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.
    Evans M; McEwan P; O'Shea R; George L
    Diabetes Ther; 2013 Jun; 4(1):27-40. PubMed ID: 23225378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
    Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
    Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy.
    Sportiello L; Rafaniello C; Scavone C; Vitale C; Rossi F; Capuano A
    Int J Cardiol; 2016 Jan; 202():731-5. PubMed ID: 26461922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of incretin-based therapies--review of the scientific evidence.
    Drucker DJ; Sherman SI; Bergenstal RM; Buse JB
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2027-31. PubMed ID: 21734003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC; Borghi C; Consoli A; Volpe M
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.